Targeted actinium-225 in vivo generators for therapy of ovarian cancer

Cancer Research

Volumn 63, Issue 16, 2003, Pages 5084-5090

  Borchardt, Paul E ^a   Yuan, Rui R ^a   Miederer, Matthias ^a   McDevitt, Michael R ^a   Scheinberg, David A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 ISOTHIOCYANATOBENZYL) 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ACTINIUM; ACTINIUM 225; INDIUM 111; ISOTHIOCYANIC ACID DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG UPTAKE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

ACTINIUM; ANIMALS; ANTIBODIES, MONOCLONAL; DIMERIZATION; FEMALE; HUMANS; INDIUM RADIOISOTOPES; MICE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0041513403     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Nikula, T. K., McDevitt, M. R., Finn, R. D., Wu, C., Kozak, R. W., Garmestani, K., Brechbiel, M. W., Curcio, M. J., Pippin, C. G., Tiffany-Jones, L., Geerlings M. W. Sr., Apostolidis, C., Molinet, R., Geerlings, M. W., Jr., Gansow, O. A., and Scheinberg, D. A. α-Emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry. J. Nucl. Med., 40: 166-176, 1999.
2. 213Bi- HuM195 (anti-CD33) in patients with leukemia. J. Nucl. Med., 40: 1935-1946, 1999.
3. McDevitt, M. R., Sgouros, G., Finn, R. D., Humm, J. L., Jurcic, J. G., Larson, S. M., and Scheinberg, D. A. Radioimmunotherapy with α-emitting nuclides. Eur. J. Nucl. Med., 25: 1341-1351, 1998.
4. McDevitt, M. R., Ma, D., Lai, L. T., Simon, J., Borchardt, P. E., Frank, R. K., Wu, K., Pellegrini, V., Curcio, M. J., Miederer, M., Bander, N. H., and Scheinberg, D. A. Tumor therapy with targeted atomic nanogenerators. Science (Wash. DC), 294: 1537-1540, 2001.
5. 213Bi generator system for therapeutic clinical applications: construction and operation. Appl. Radiat. Isot., 50: 895-904, 1999.
6. McGuire, W. P. Primary treatment of epithelial ovarian malignancies. Cancer (Phila.), 71(Suppl.): 1541-1550, 1993.
7. Bolis, G., Villa, A., Guarnerio, P., Ferraris, C., Gavoni, N., Giardina, G., Melpignano, M., Scarfone, G., Zanaboni, F., and Parazzini, F. Survival of women with advanced ovarian cancer and complete pathological response at second-look laparotomy. Cancer (Phila.), 77: 128-131, 1996.
8. Epenetos, A. A., Munro, A. J., Stewart, S., Rampling, R., Lambert, H. E., McKenzie, C. G., Soutter, P., Rahemtulla, A., Hooker, G., and Sivolapenko, G. B. Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J. Clin. Oncol., 5: 1890-1899, 1987.
9. Crippa, F., Bolis, G., Seregni, E., Gavoni, N., Scarfone, G., Ferraris, C., Buraggi, G. L., and Bombardieri, E. Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131-Mov18: Clinical results in patients with minimal disease of ovarian cancer. Eur. J. Cancer, 31: 686-690, 1995.
10. 186Re-labeled monoclonal antibody: methods and results. Cancer Res., 55(Suppl.): 5817s-5822s, 1995.
11. Nicholson, S., Gooden, C. S., Hird, V., Maraveyas, A., Mason, P., Lambert, H. E., Meares, C. F., and Epenetos. A. A. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: A matched analysis. Oncol. Rep., 5: 223-226, 1998.
12. Buijs, W. C. A. M., Tibben, J. G., Boerman, O. C., Molthoff, C. F. M., Massuger, L. F. A. G., Koenders, E. B., Schijf, C. P. T., Siegel, J. A., and Corstens, F. H. M. Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. Eur. J. Nucl. Med., 25: 1552-1561, 1998.
13. Meredith, R. F., Partridge, E. E., Alvarez, R. D., Khazaeli, M. B., Plott, G., Russell, C. D., Wheeler, R. H., Liu, T., Grizzle, W. E., Schlom, J., and LoBuglio, A. F. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J. Nucl. Med., 37: 1491-1496, 1996.
14. HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA, 89: 4285-4289, 1992.
15. Co, M. S., Avdalovic, N. M., Caron, P. C., Avdalovic, M. V., Scheinberg, D. A., and Queen, C. Chimeric and humanized antibodies with specificity for the CD33 antigen. J. Immunol., 148: 1149-1154, 1991.
16. Mujoo, K., Maneval, D. C., Anderson, S. C., and Gutterman, J. U. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene, 12: 1617-1623, 1996.
17. McDevitt, M. R., Ma, D., Simon, J., Frank, R. K., Kiefer, G. E., and Scheinberg, D. A. Design and synthesis of Actinium-225 Radioimmunopharmaceuticals. Appl. Radiat. Isot., 57: 841-847, 2002.
18. Nikula, T. K., Curcio, M. J., Brechbiel, M. W., Gansow, O. A., Finn, R. D., and Scheinberg, D. A. A rapid single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nucl. Med. Biol., 22: 387-390, 1995.
19. Concin, N., Zeillinger, C., Stimpfel, M., Schiebel, I., Tong, D., Wolff, U., Reiner, A., Leodolter, S., and Zeillinger, R. p53-dependent radioresistance in ovarian cancer cell lines. Cancer Lett., 150: 191-199, 2000.
20. Scheinberg, D. A., and Strand, M. Kinetic and catabolic considerations of monoclonal antibody targeting in erythroleukemic mice. Cancer Res., 43: 265-272, 1983.
21. 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. Cancer Res., 59: 2635-2643, 1999.
22. Behr, T. M., Sgouros, G., Stabin, M. G., Behe, M., Angerstein, C., Blumenthal, R. D., Apostolidis, C., Molinet, R., Sharkey, R. M., Koch, L., Goldenberg, D. M., and Becker, W. Studies on the red marrow dosimetry in radioimmunotherapy: An experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with β-, Auger/conversion electron-, or α-emitters. Clin. Cancer Res., 5: 3031s-3043s, 1999.
23. Sgouros, G., Ballangrud, A. M., Hamacher, K. A., Jurcic, J. G., Panageas, K. S., McDevitt, M. R., Finn, R. D., Larson, S. M., and Scheinberg, D. A. β- vs. α-emitter dose-response analysis in patients. J. Nucl. Med., 41(Suppl.): 82P, 2000.
24. Pouget, J. P., and Mather, S. J. General aspects of the cellular response to low- and high-LET radiation. Eur. J. Nucl. Med., 28: 541-561, 2001.
25. Wilbur, D. S. Potential use of α emitting radionuclides in the treatment of cancer. Antibody Immunoconjug. Radiopharm., 4: 85-97, 1991.
26. Ward, B. G., and Wallace, K. Localization of monoclonal antibody HMFG2 after intravenous and intraperitoneal injection into nude mice bearing subcutaneous and intraperitoneal human ovarian cancer xenografts. Cancer Res., 47: 4714-4718, 1987.
27. Rowlinson, G., Snook, D., Busza, A., and Epenetos, A. A. Antibody-guided localization of intraperitoneal tumors following intraperitoneal or intravenous administration. Cancer Res., 47: 6528-6531, 1987.
28. 211At in nude mice with intraperitoneally growing ovarian cancer xenografts. Acta Oncol., 39: 741-745, 2000.
29. Gadina, M., Canevari, S., Ripamonti, M., Mariani, M., and Colnaghi, M. I. Preclinical pharmacokinetics and localization studies of the radioiodinated anti-ovarian carcinoma MAb MOv18. Nucl. Med. Biol., 18: 403-408, 1991.
30. Chatal, J. F., Saccavini, J. C., Gestin, J. F., Thedrez, P., Curtet, C., Kremer, M., Guerreau, D., Nolibe, D., Fumoleau, P., and Gulliard, Y. Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian cancer. Cancer Res., 49: 3087-3094, 1989.
31. Kennel, S. J., Stabin, M., Roeske, J. C., Foote, L. J., Lankford, P. K., Terzaghi-Howe, M., Patterson, H., Barkenbus, J., Popp, D. M., and Mirzadeh, S. Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells. Radiat. Res., 151: 244-256, 1999.
32. Wolff, E. A., Schreiber, G. J., Cosand, W. L., and Raff, H. V. Monoclonal antibody homodimers: Enhanced antitumor activity in nude mice. Cancer Res., 53: 2560-2565, 1993.
33. Caron, P. C., Laird, W., Co, M. S., Avdalovic, N. M., Queen, C., and Scheinberg, D. A. Engineered humanized dimeric forms of IgG are more effective antibodies. J. Exp. Med., 176: 1191-1195, 1992.
34. Pardridge, W. M., Bickel, U., Buciak, J., Yang, J., Diagne, A., and Aepinus, C. Cationization of a monoclonal antibody to the human immunodeficiency virus REV protein enhances cellular uptake but does not impair antigen binding of the antibody. Immunol. Lett., 42: 191-195, 1994.
35. Berchuck, A., Kamel, A., Whitaker, R., Kerns, B., Olt, G., Kinney, R., Soper, J. T., Dodge, R., Clarke-Pearson, D. L., Marks, P., McKenzie, S., Yin, S., and Bast, R. C., Jr. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res., 50: 4087-4091, 1990.
36. Rubin, S. C., Finstad, C. L., Wong, G. Y., Almadrones, L., Plante, M., and Lloyd, K. O. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis. Am. J. Obstet. Gynecol., 168: 162-169, 1993.
37. Miotti, S., Canevari, S., Menard, S., Mezzanzanica, D., Porro, G., Pupa, S. M., Regazzoni, M., Tagliabue, E., and Colnaghi, M. I. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int. J. Cancer, 39: 297-303, 1987.